Mabion (WAR:MAB) E10: zł-3.51 (As of Mar. 2026)


WAR:MAB Mabion SA WAR:MAB
29 GF Score
Price zł7.59
GF Value zł2.10
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Mabion E10?

Mabion WAR:MAB -2.69% 29 E10 is zł-3.51 as of Mar. 2026. GuruFocus rates WAR:MAB with a GF Score™ of 29/100 and a GF Value™ of zł2.10 (Significantly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Mabion's adjusted earnings per share data for the three months ended in Mar. 2026 was zł-0.600. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is zł-3.51 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average E10 Growth Rate was 0.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Mabion was 0.90% per year. The lowest was -3.70% per year. And the median was -1.40% per year.

As of today (2026-06-27), Mabion's current stock price is zł7.59. Mabion's E10 for the quarter that ended in Mar. 2026 was zł-3.51. Mabion's Shiller PE Ratio of today is .


Mabion  (WAR:MAB) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Mabion E10 Related Terms


Mabion E10 Historical Data

* Premium members only.

The historical data trend for Mabion's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mabion E10 Chart

Mabion Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.35 -3.70 -3.60 -3.74 -3.60

Mabion Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.87 -3.97 -4.01 -3.60 -3.51

WAR:MAB vs VRTX, REGN, ALNY: E10 Comparison

For the Biotechnology subindustry, Mabion's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mabion Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mabion's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Mabion's Shiller PE Ratio falls into.


WAR:MAB
29GF Score
Mabion SA WAR:MAB
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mabion E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Mabion's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.6/158.3232*158.3232
=-0.600

Current CPI (Mar. 2026) = 158.3232.

Mabion Quarterly Data

per share eps CPI Adj_EPS
201606 -1.210 99.552 -1.924
201609 -1.230 99.064 -1.966
201612 -1.490 100.366 -2.350
201703 -1.100 101.018 -1.724
201706 -1.060 101.180 -1.659
201709 -0.770 101.343 -1.203
201712 -1.640 102.564 -2.532
201803 -1.220 102.564 -1.883
201806 -2.050 103.378 -3.140
201809 -0.950 103.378 -1.455
201812 -1.200 103.785 -1.831
201903 -1.090 104.274 -1.655
201906 -1.220 105.983 -1.823
201909 -1.220 105.983 -1.823
201912 -1.110 107.123 -1.641
202003 -1.450 109.076 -2.105
202006 -0.800 109.402 -1.158
202009 -0.660 109.320 -0.956
202012 -1.150 109.565 -1.662
202103 -1.240 112.658 -1.743
202106 -0.150 113.960 -0.208
202109 -0.970 115.588 -1.329
202112 2.300 119.088 3.058
202203 0.460 125.031 0.582
202206 0.320 131.705 0.385
202209 -0.310 135.531 -0.362
202212 0.970 139.113 1.104
202303 1.020 145.950 1.106
202306 0.940 147.009 1.012
202309 0.670 146.113 0.726
202312 -0.080 147.741 -0.086
202403 1.090 149.044 1.158
202406 0.640 150.997 0.671
202409 -1.010 153.439 -1.042
202412 -1.100 154.660 -1.126
202503 -0.940 157.021 -0.948
202506 -0.950 157.509 -0.955
202509 -0.670 157.998 -0.671
202512 -1.310 158.323 -1.310
202603 -0.600 158.323 -0.600

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of zł-3.51 mean?
Mabion (WAR:MAB) has a E10 of zł-3.51 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Mabion and its competitors.
Is Mabion's E10 too high?
Mabion's current E10 is zł-3.51. Overall, Mabion has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mabion's E10 compare to VRTX and REGN?
Mabion's E10 of zł-3.51 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Mabion and its competitors. Mabion's current E10 is zł-3.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mabion stock overvalued right now?
Based on GuruFocus' analysis, Mabion (WAR:MAB) is currently considered Significantly Overvalued. The stock's GF Value™ is zł2.10, compared to a current price of zł7.59 — trading 261.4% above its estimated fair value. The current E10 is zł-3.51. Mabion's overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Mabion (WAR:MAB), the current E10 is zł-3.51 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mabion (WAR:MAB) Overvalued in 2026?

Based on GuruFocus' analysis, Mabion stock appears to be overvalued. The current stock price of zł7.59 is trading 261.4% above its estimated GF Value™ of zł2.10. GuruFocus considers Mabion to be Significantly Overvalued.

Key valuation signals for WAR:MAB:

  • E10: zł-3.51
  • GF Value™: zł2.10 vs. price of zł7.59 (261.4% above fair value)
  • GF Score™: 29/100 with 5 warning signs

No single metric tells the full story. See the WAR:MAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Mabion Business Description

Other Exchanges 272:Germany
Address ul. Gen. Mariana Langiewicza 60, Konstantynow Lodzki, POL, 95-050
Mabion SA is a Polish biotechnology company focused on developing and launching modern biotechnology drugs based on monoclonal antibody technology. The drugs developed by the company are targeted treatments, characterized by the drug's ability to recognize the factor causing cancer and interact with this factor only. The company is working on the development of its main priority drug, referred to as the MabionCD20 drug. The therapeutic uses of MabionCD20 are for Non-Hodgkin's lymphoma, Leukemia, and Rheumatoid Arthritis.
29GF Score

Get the complete analysis for WAR:MAB

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł7.59
Price
zł2.10
GF Value